- Home
- THRD vs NPCT Comparison
THRD vs NPCT Comparison
Compare THRD & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- NPCT
- Stock Information
- Founded
- THRD 2019
- NPCT 2020
- Country
- THRD United States
- NPCT United States
- Employees
- THRD N/A
- NPCT N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- THRD Health Care
- NPCT Finance
- Exchange
- THRD Nasdaq
- NPCT Nasdaq
- Market Cap
- THRD 335.2M
- NPCT 308.5M
- IPO Year
- THRD 2022
- NPCT N/A
- Fundamental
- Price
- THRD $3.47
- NPCT $10.85
- Analyst Decision
- THRD Buy
- NPCT
- Analyst Count
- THRD 3
- NPCT 0
- Target Price
- THRD $14.00
- NPCT N/A
- AVG Volume (30 Days)
- THRD 1.2M
- NPCT 107.1K
- Earning Date
- THRD 03-25-2025
- NPCT 01-01-0001
- Dividend Yield
- THRD N/A
- NPCT 9.82%
- EPS Growth
- THRD N/A
- NPCT N/A
- EPS
- THRD N/A
- NPCT N/A
- Revenue
- THRD N/A
- NPCT N/A
- Revenue This Year
- THRD N/A
- NPCT N/A
- Revenue Next Year
- THRD N/A
- NPCT N/A
- P/E Ratio
- THRD N/A
- NPCT N/A
- Revenue Growth
- THRD N/A
- NPCT N/A
- 52 Week Low
- THRD $3.18
- NPCT $8.58
- 52 Week High
- THRD $16.94
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- THRD 25.71
- NPCT 55.61
- Support Level
- THRD $3.18
- NPCT $10.76
- Resistance Level
- THRD $3.70
- NPCT $10.97
- Average True Range (ATR)
- THRD 0.31
- NPCT 0.07
- MACD
- THRD 0.10
- NPCT -0.00
- Stochastic Oscillator
- THRD 13.26
- NPCT 56.99
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.